Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y2R4
UPID:
DDX52_HUMAN
Alternative names:
ATP-dependent RNA helicase ROK1-like; DEAD box protein 52
Alternative UPACC:
Q9Y2R4; Q86YG1; Q8N213; Q9NVE0; Q9Y482
Background:
The Probable ATP-dependent RNA helicase DDX52, also known as ATP-dependent RNA helicase ROK1-like and DEAD box protein 52, plays a crucial role in ribosome biogenesis, akin to its counterparts. It is speculated to regulate cell cycle progression by modulating the translation of mRNAs with a terminal oligo pyrimidine (TOP) motif in their 5' UTRs, including GTPBP4.
Therapeutic significance:
Understanding the role of Probable ATP-dependent RNA helicase DDX52 could open doors to potential therapeutic strategies, especially in the realm of diseases where ribosome biogenesis and cell cycle regulation are compromised.